Cellyan Biotechnology Co., Ltd (HKPD) Stock Price & Analysis
Cellyan Biotechnology Co., Ltd (HKPD) — MoonshotScore 39/100 (Weak band), calculated Nov 18, 2026. Price $1.34 (+1.13%), as of the Nov 19, 2026 trading session; market cap $3.32M.
Educational signal · not a buy or sell recommendation · How to read this
Cellyan Biotechnology Co., Ltd · HKPD
Cellyan Biotechnology Co., Ltd (HKPD) is an investment holding entity specializing in international sourcing and distribution of over-the-counter (OTC) pharmaceuticals across Hong Kong and mainland China. The company also provides comprehensive e-commerce supply chain management and logistical support, serving a diverse clientele including e-commerce logistics partners, merchants, and pharmaceutical distributors.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Cellyan Biotechnology Co. (HKPD)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Cheap, but a strained balance sheet, stalling growth and average quality, and the price trend has turned against it. The score also carries a risk penalty for being loss-making and burning cash. Business Quality: Average; Financial Safety: Strained; Valuation: Cheap; Growth Durability: Shrinking; Momentum: Falling.
- quarterly revenue $6M (Q4 FY2026, quarter ended Mar 31, 2026)
- Altman Z 2.27 · Piotroski F 4
- ROE -15.6% · ROA -5.6% · current ratio 3.86
Holding back: balance-sheet strain, soft growth, weak price trend
Helping: an attractive price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 38 | Weak | |
| 38 | Weak | |
| 38 | Weak | |
| 38 | Weak | |
| 39 | Weak | |
| 39 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.34 | |
| Change on the day | +1.13% | |
| 52-week range | $1.34 – $29.00 | |
| Market capitalisation | $3.32M | — |
| Shares traded on the day | 12.2K |
Price & events
Other perspectives
Council score for Cellyan Biotechnology Co. (HKPD): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Cellyan Biotechnology Co. (HKPD), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Cellyan Biotechnology Co., Ltd (HKPD) is the company analyzed here. It employs 11 people and is led by Chenyu Liang. In Q4 FY2026 it reported revenue of $6M and net income of -$1M. The market values it at $3.32M.
What do the latest results show for Cellyan Biotechnology Co. (HKPD)?
Short answer · as of
The most recent reported quarter, Q4 FY2026, carried revenue of $6M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2026 | $6M | -$1M | -$0.72 (diluted) |
| Q2 FY2026 | $7M | $153,735 | $0.28 (diluted) |
| Q4 FY2025 | $9M | -$855,616 | -$1.65 (diluted) |
| Q2 FY2025 | $11M | $828,560 | $1.66 (diluted) |
What are the financial strengths and risks for Cellyan Biotechnology Co. (HKPD)?
Short answer
The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is balance-sheet strain, soft growth, weak price trend. The distress and quality screens read Altman Z 2.27 · Piotroski F 4. Trailing ratios: ROE -15.6% · ROA -5.6% · current ratio 3.86.
How does Cellyan Biotechnology Co. compare with its peers?
Short answer
Cellyan Biotechnology Co.'s score ranks 7th of 8 in the bounded comparison shown, against 7 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $46.66 Nov 19, 2026 | $2.96B | 96 5-pillar Nov 18, 2026 | |
| $1062.16 Nov 19, 2026 | $123B | 92 5-pillar Nov 18, 2026 | |
| $272.37 Nov 19, 2026 | $63.0B | 88 5-pillar Nov 18, 2026 | |
| $341.25 Nov 19, 2026 | $65.1B | 86 5-pillar Nov 18, 2026 | |
| $84.80 Nov 19, 2026 | $9.37B | 73 5-pillar Nov 18, 2026 | |
| $49.60 Nov 19, 2026 | $2.35B | 63 5-pillar Nov 18, 2026 | |
| Cellyan Biotechnology Co. (HKPD) — this page | $1.34 | $3.32M | 39 |
| $0.09 Nov 18, 2026 | $6.60M | 30 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held HKPD in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported HKPD in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Cellyan Biotechnology Co. (HKPD)?
What Investors Ask About Cellyan Biotechnology Co. (HKPD)
These answers are editorial: 1 of these 9 answers is drawn from the HKPD research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for HKPD?
HKPD carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is HKPD a good stock to buy?
Stock Expert AI does not rate HKPD buy, sell or hold. Cellyan Biotechnology Co., Ltd carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the HKPD stock price today?
The last price recorded for Cellyan Biotechnology Co., Ltd (HKPD), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is Cellyan Biotechnology Co., Ltd's core business model and market focus?
Cellyan Biotechnology Co., Ltd operates as an investment holding entity with a primary focus on the over-the-counter (OTC) pharmaceutical sector.
What are the key factors to evaluate for HKPD?
Cellyan Biotechnology Co., Ltd (HKPD) holds a MoonshotScore in the low range. The core business involves international sourcing and distribution of over-the-counter (OTC) medications, complemented by e-commerce supply chain management and logistical support in Hong Kong and mainland China. Not financial advice.
How frequently does HKPD data refresh on this page?
HKPD's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven HKPD's recent stock price performance?
Cellyan Biotechnology Co., Ltd (HKPD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on the over-the-counter (OTC) pharmaceutical sector in Hong Kong and mainland China. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HKPD overvalued or undervalued right now?
Cellyan Biotechnology Co., Ltd (HKPD) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research HKPD before investing?
Before investing in Cellyan Biotechnology Co., Ltd (HKPD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 7 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com